The clinical and integrated management of COPD

G. Bettoncelli, F. Blasi, V. Brusasco, S. Centanni, A. Corrado, F. De Benedetto, F. De Michele, G. U. Di Maria, C. F. Donner, F. Falcone, C. Mereu, S. Nardini, F. Pasqua, M. Polverino, A. Rossi, C. M. Sanguinetti

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

COPD is a chronic pathological condition of the respiratory system characterized by persistent and partially reversible airflow obstruction, to which variably contribute remodeling of bronchi (chronic bronchitis), bronchioles (small airway disease) and lung parenchyma (pulmonary emphysema). COPD can cause important systemic effects and be associated with complications and comorbidities. The diagnosis of COPD is based on the presence of respiratory symptoms and/or a history of exposure to risk factors, and the demonstration of airflow obstruction by spirometry. GARD of WHO has defined COPD "a preventable and treatable disease". The integration among general practitioner, chest physician as well as other specialists, whenever required, assures the best management of the COPD person, when specific targets to be achieved are well defined in a diagnostic and therapeutic route, previously designed and shared with appropriateness. The first-line pharmacologic treatment of COPD is represented by inhaled long-acting bronchodilators. In symptomatic patients, with pre-bronchodilator FEV1 <60%predicted and ≥ 2 exacerbations/year, ICS may be added to LABA. The use of fixed-dose, single-inhaler combination may improve the adherence to treatment. Long term oxygen therapy (LTOT) is indicated in stable patients, at rest while receiving the best possible treatment, and exhibiting a PaO2 ≤ 55 mmHg (SO2 55%. Respiratory rehabilitation is addressed to patients with chronic respiratory disease in all stages of severity who report symptoms and limitation of their daily activity. It must be integrated in an individual patient tailored treatment as it improves dyspnea, exercise performance, and quality of life. Acute exacerbation of COPD is a sudden worsening of usual symptoms in a person with COPD, over and beyond normal daily variability that requires treatment modification. The pharmacologic therapy can be applied at home and includes the administration of drugs used during the stable phase by increasing the dose or modifying the route, and adding, whenever required, drugs as antibiotics or systemic corticosteroids. In case of patients who because of COPD severity and/or of exacerbations do not respond promptly to treatment at home hospital admission should be considered. Patients with "severe or "very severe COPD who experience exacerbations should be carried out in respiratory unit, based on the severity of acute respiratory failure. An integrated system is required in the community in order to ensure adequate treatments also outside acute care hospital settings and rehabilitation centers. This article is being simultaneusly published in Multidisciplinary Respiratory Medicine 2014; 9:25.

Original languageEnglish
Pages (from-to)3-21
Number of pages19
JournalSarcoidosis Vasculitis and Diffuse Lung Diseases
Volume31
Publication statusPublished - 2014

Fingerprint

Chronic Obstructive Pulmonary Disease
Therapeutics
Bronchodilator Agents
Bronchioles
Pulmonary Medicine
Pulmonary Emphysema
Rehabilitation Centers
Nebulizers and Vaporizers
Spirometry
Chronic Bronchitis
Bronchi
Respiratory Insufficiency
Pharmaceutical Preparations
Respiratory System
Dyspnea
General Practitioners
Lung Diseases
Comorbidity
Adrenal Cortex Hormones
Chronic Disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bettoncelli, G., Blasi, F., Brusasco, V., Centanni, S., Corrado, A., De Benedetto, F., ... Sanguinetti, C. M. (2014). The clinical and integrated management of COPD. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 31, 3-21.

The clinical and integrated management of COPD. / Bettoncelli, G.; Blasi, F.; Brusasco, V.; Centanni, S.; Corrado, A.; De Benedetto, F.; De Michele, F.; Di Maria, G. U.; Donner, C. F.; Falcone, F.; Mereu, C.; Nardini, S.; Pasqua, F.; Polverino, M.; Rossi, A.; Sanguinetti, C. M.

In: Sarcoidosis Vasculitis and Diffuse Lung Diseases, Vol. 31, 2014, p. 3-21.

Research output: Contribution to journalReview article

Bettoncelli, G, Blasi, F, Brusasco, V, Centanni, S, Corrado, A, De Benedetto, F, De Michele, F, Di Maria, GU, Donner, CF, Falcone, F, Mereu, C, Nardini, S, Pasqua, F, Polverino, M, Rossi, A & Sanguinetti, CM 2014, 'The clinical and integrated management of COPD', Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 31, pp. 3-21.
Bettoncelli G, Blasi F, Brusasco V, Centanni S, Corrado A, De Benedetto F et al. The clinical and integrated management of COPD. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2014;31:3-21.
Bettoncelli, G. ; Blasi, F. ; Brusasco, V. ; Centanni, S. ; Corrado, A. ; De Benedetto, F. ; De Michele, F. ; Di Maria, G. U. ; Donner, C. F. ; Falcone, F. ; Mereu, C. ; Nardini, S. ; Pasqua, F. ; Polverino, M. ; Rossi, A. ; Sanguinetti, C. M. / The clinical and integrated management of COPD. In: Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2014 ; Vol. 31. pp. 3-21.
@article{fcaf5a8d1abf4812a732a8c888f8d522,
title = "The clinical and integrated management of COPD",
abstract = "COPD is a chronic pathological condition of the respiratory system characterized by persistent and partially reversible airflow obstruction, to which variably contribute remodeling of bronchi (chronic bronchitis), bronchioles (small airway disease) and lung parenchyma (pulmonary emphysema). COPD can cause important systemic effects and be associated with complications and comorbidities. The diagnosis of COPD is based on the presence of respiratory symptoms and/or a history of exposure to risk factors, and the demonstration of airflow obstruction by spirometry. GARD of WHO has defined COPD {"}a preventable and treatable disease{"}. The integration among general practitioner, chest physician as well as other specialists, whenever required, assures the best management of the COPD person, when specific targets to be achieved are well defined in a diagnostic and therapeutic route, previously designed and shared with appropriateness. The first-line pharmacologic treatment of COPD is represented by inhaled long-acting bronchodilators. In symptomatic patients, with pre-bronchodilator FEV1 <60{\%}predicted and ≥ 2 exacerbations/year, ICS may be added to LABA. The use of fixed-dose, single-inhaler combination may improve the adherence to treatment. Long term oxygen therapy (LTOT) is indicated in stable patients, at rest while receiving the best possible treatment, and exhibiting a PaO2 ≤ 55 mmHg (SO2 55{\%}. Respiratory rehabilitation is addressed to patients with chronic respiratory disease in all stages of severity who report symptoms and limitation of their daily activity. It must be integrated in an individual patient tailored treatment as it improves dyspnea, exercise performance, and quality of life. Acute exacerbation of COPD is a sudden worsening of usual symptoms in a person with COPD, over and beyond normal daily variability that requires treatment modification. The pharmacologic therapy can be applied at home and includes the administration of drugs used during the stable phase by increasing the dose or modifying the route, and adding, whenever required, drugs as antibiotics or systemic corticosteroids. In case of patients who because of COPD severity and/or of exacerbations do not respond promptly to treatment at home hospital admission should be considered. Patients with {"}severe or {"}very severe COPD who experience exacerbations should be carried out in respiratory unit, based on the severity of acute respiratory failure. An integrated system is required in the community in order to ensure adequate treatments also outside acute care hospital settings and rehabilitation centers. This article is being simultaneusly published in Multidisciplinary Respiratory Medicine 2014; 9:25.",
author = "G. Bettoncelli and F. Blasi and V. Brusasco and S. Centanni and A. Corrado and {De Benedetto}, F. and {De Michele}, F. and {Di Maria}, {G. U.} and Donner, {C. F.} and F. Falcone and C. Mereu and S. Nardini and F. Pasqua and M. Polverino and A. Rossi and Sanguinetti, {C. M.}",
year = "2014",
language = "English",
volume = "31",
pages = "3--21",
journal = "Sarcoidosis Vasculitis and Diffuse Lung Diseases",
issn = "1124-0490",
publisher = "Mattioli 1885 S.p.A.",

}

TY - JOUR

T1 - The clinical and integrated management of COPD

AU - Bettoncelli, G.

AU - Blasi, F.

AU - Brusasco, V.

AU - Centanni, S.

AU - Corrado, A.

AU - De Benedetto, F.

AU - De Michele, F.

AU - Di Maria, G. U.

AU - Donner, C. F.

AU - Falcone, F.

AU - Mereu, C.

AU - Nardini, S.

AU - Pasqua, F.

AU - Polverino, M.

AU - Rossi, A.

AU - Sanguinetti, C. M.

PY - 2014

Y1 - 2014

N2 - COPD is a chronic pathological condition of the respiratory system characterized by persistent and partially reversible airflow obstruction, to which variably contribute remodeling of bronchi (chronic bronchitis), bronchioles (small airway disease) and lung parenchyma (pulmonary emphysema). COPD can cause important systemic effects and be associated with complications and comorbidities. The diagnosis of COPD is based on the presence of respiratory symptoms and/or a history of exposure to risk factors, and the demonstration of airflow obstruction by spirometry. GARD of WHO has defined COPD "a preventable and treatable disease". The integration among general practitioner, chest physician as well as other specialists, whenever required, assures the best management of the COPD person, when specific targets to be achieved are well defined in a diagnostic and therapeutic route, previously designed and shared with appropriateness. The first-line pharmacologic treatment of COPD is represented by inhaled long-acting bronchodilators. In symptomatic patients, with pre-bronchodilator FEV1 <60%predicted and ≥ 2 exacerbations/year, ICS may be added to LABA. The use of fixed-dose, single-inhaler combination may improve the adherence to treatment. Long term oxygen therapy (LTOT) is indicated in stable patients, at rest while receiving the best possible treatment, and exhibiting a PaO2 ≤ 55 mmHg (SO2 55%. Respiratory rehabilitation is addressed to patients with chronic respiratory disease in all stages of severity who report symptoms and limitation of their daily activity. It must be integrated in an individual patient tailored treatment as it improves dyspnea, exercise performance, and quality of life. Acute exacerbation of COPD is a sudden worsening of usual symptoms in a person with COPD, over and beyond normal daily variability that requires treatment modification. The pharmacologic therapy can be applied at home and includes the administration of drugs used during the stable phase by increasing the dose or modifying the route, and adding, whenever required, drugs as antibiotics or systemic corticosteroids. In case of patients who because of COPD severity and/or of exacerbations do not respond promptly to treatment at home hospital admission should be considered. Patients with "severe or "very severe COPD who experience exacerbations should be carried out in respiratory unit, based on the severity of acute respiratory failure. An integrated system is required in the community in order to ensure adequate treatments also outside acute care hospital settings and rehabilitation centers. This article is being simultaneusly published in Multidisciplinary Respiratory Medicine 2014; 9:25.

AB - COPD is a chronic pathological condition of the respiratory system characterized by persistent and partially reversible airflow obstruction, to which variably contribute remodeling of bronchi (chronic bronchitis), bronchioles (small airway disease) and lung parenchyma (pulmonary emphysema). COPD can cause important systemic effects and be associated with complications and comorbidities. The diagnosis of COPD is based on the presence of respiratory symptoms and/or a history of exposure to risk factors, and the demonstration of airflow obstruction by spirometry. GARD of WHO has defined COPD "a preventable and treatable disease". The integration among general practitioner, chest physician as well as other specialists, whenever required, assures the best management of the COPD person, when specific targets to be achieved are well defined in a diagnostic and therapeutic route, previously designed and shared with appropriateness. The first-line pharmacologic treatment of COPD is represented by inhaled long-acting bronchodilators. In symptomatic patients, with pre-bronchodilator FEV1 <60%predicted and ≥ 2 exacerbations/year, ICS may be added to LABA. The use of fixed-dose, single-inhaler combination may improve the adherence to treatment. Long term oxygen therapy (LTOT) is indicated in stable patients, at rest while receiving the best possible treatment, and exhibiting a PaO2 ≤ 55 mmHg (SO2 55%. Respiratory rehabilitation is addressed to patients with chronic respiratory disease in all stages of severity who report symptoms and limitation of their daily activity. It must be integrated in an individual patient tailored treatment as it improves dyspnea, exercise performance, and quality of life. Acute exacerbation of COPD is a sudden worsening of usual symptoms in a person with COPD, over and beyond normal daily variability that requires treatment modification. The pharmacologic therapy can be applied at home and includes the administration of drugs used during the stable phase by increasing the dose or modifying the route, and adding, whenever required, drugs as antibiotics or systemic corticosteroids. In case of patients who because of COPD severity and/or of exacerbations do not respond promptly to treatment at home hospital admission should be considered. Patients with "severe or "very severe COPD who experience exacerbations should be carried out in respiratory unit, based on the severity of acute respiratory failure. An integrated system is required in the community in order to ensure adequate treatments also outside acute care hospital settings and rehabilitation centers. This article is being simultaneusly published in Multidisciplinary Respiratory Medicine 2014; 9:25.

UR - http://www.scopus.com/inward/record.url?scp=84977455144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977455144&partnerID=8YFLogxK

M3 - Review article

C2 - 24820963

AN - SCOPUS:84977455144

VL - 31

SP - 3

EP - 21

JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases

JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases

SN - 1124-0490

ER -